J. Goldman & Co
IMMX icon

J. Goldman & Co’s Immix Biopharma IMMX Stock Holding History

J. Goldman & Co’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Sell
198,732
-29,357
-13% -$272K 0.05% 334
2026
Q1 		$2.08M Buy
228,089
+109,828
+93% +$807K 0.06% 312
2025
Q4 		$619K Buy
+118,261
New +$487K 0.02% 440

Other funds holding IMMX

Jupiter Topco
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

J. Goldman & Co's IMMX Position: Q2 2026 in Review

J. Goldman & Co reduced its Immix Biopharma (IMMX) stake by 13% in Q2 2026, selling an estimated $272K and leaving 198,732 shares worth $2.05M. The position accounts for 0.05% of the portfolio, ranked #334.

J. Goldman & Co first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.08M in Q1 2026. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • J. Goldman & Co held 198,732 shares of Immix Biopharma worth $2.05M as of Q2 2026.
  • J. Goldman & Co sold 29,357 Immix Biopharma shares in Q2 2026, an estimated $272K.
  • Immix Biopharma made up 0.05% of J. Goldman & Co's portfolio in Q2 2026, its #334 holding.
  • J. Goldman & Co first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Immix Biopharma position peaked at $2.08M in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.